Gastrointestinal Cancer News

Colonoscopy screening was mostly effective in preventing colorectal cancer in patients aged 70 years to 74 years, according to research published in the Annals of Internal Medicine.

Nearly half of patients with cancer expected that their tumors would shrink while on a phase 1 study, although the typical response rate observed in early-phase trials ranges from 4% to 20%, according to results of a single-center, prospective, quantitative study.

Black cancer survivors appeared more likely than white survivors to face lasting debt and limit their medical care due to cost concerns, according to study results presented at the AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

Fox Chase Cancer Center announced several faculty appointments.

The Asian Liver Center and twoXAR announced a new cooperation in treating hepatocellular carcinoma, with the ultimate goal of finding an alternative to Nexavar.

Elderly patients with hepatocellular carcinoma taking sorafenib fared as well as younger patients, according to results published in the European Journal of Gastroenterology and Hepatology.

Allergan plc announced agreements with two different biopharmaceutical companies — a move it said significantly increases its nonalcoholic steatohepatitis and gastrointestinal research and development capacities.

Treatment with and response to methylnaltrexone for opioid-induced constipation appeared associated with improved OS in patients with advanced cancers, according to a post-hoc analysis of two randomized trials.

While prior studies have linked regular use of non-steroidal anti-inflammatory drugs with a reduced risk for esophageal cancer, a recent study found NSAID use was not associated with a reduced risk for developing the cancer precursor Barrett’s esophagus.

Blueprint Medicines Corporation announced a new drug discovery program intended for patients with a rare form of liver cancer, according to a press release issued by the company.